Tazemetostat for the Treatment of Pediatric Patients with Malignant Rhabdoid Tumors and Other INI 1-Negative Tumors

Presentation to the Pediatric Subcommittee of the Oncology Drugs Advisory Committee

June 28, 2016
Agenda

• Tazemetostat background and preclinical data
• Relevance of EZH2 to childhood tumors
• Regulatory history
• Clinical trials experience in adults
• Pediatric phase 1 study and development program
• Challenges to development
• Summary
Antagonism of PRC2 and SWI/SNF-Dependent Chromatin Remodeling in Cancer

- SWI/SNF and PRC2 are chromatin remodeling complexes which promote or inhibit, respectively, gene transcription involved with cell cycle arrest and terminal differentiation.

- Loss of SWI/SNF subunits INI1 or SMARCA4 in tumors upsets the balance between gene activation and repression, resulting in:
  - hyper-repression of PRC2 target genes
  - potentiation of stem cell programs
  - oncogenic transformation

- Tumors may be targeted by their oncogenic dependency on EZH2, the catalytic subunit of PRC2 that generates the transcriptionally repressive H3K27me1, H3K27me2, and H3K27me3 histone marks.

Adapted from Wilson 2010
Tazemtostat (EPZ-6438): Potent and Highly Selective EZH2 Inhibitor

**Potent Target Inhibition**

\[
\text{Ki} \leq 2.5 \text{ nM}
\]

**Selective for EZH2**

- Potent and selective SAM-competitive inhibitor of EZH2
- Elicits a time- and dose-dependent cellular reduction in H3K27me3 levels
- Orally bioavailable
INI1- and SMARCA4-Negative Rhabdoid Tumor Models are Sensitive to Tazemetostat

In vitro and in vivo cell killing of mutant INI1 MRT cells

In vitro and in vivo cell killing of mutant SMARCA4 MRTO cells

Knutson et al. PNAS, 2013
Penebre et al, EORTC, 2015
2013 Accomplishments

Malignant Rhabdoid Tumors (MRT)

- Genetic alteration in chromosome 22q11
  - Immunostaining for INI-1/Baf47 is diagnostic
- Genetic predisposition: monoallelic germline alteration in ~25% to 35% of pediatric patients
- Diverse anatomic locations
  - Kidney: Rhabdoid tumor of the kidney (RTK)
  - Central nervous system: Atypical teratoid rhabdoid tumor (ATRT)
  - Soft tissues, liver, neck, lungs, nerve plexus (MRT)
  - May have synchronous tumors in brain and ex-CNS
Rhabdoid Tumor of Kidney

- Historically included in National Wilms Tumor Study (NWTS) Group and Intergroup Rhabdomyosarcoma Study (IRS) protocols
- Represents <2% of childhood kidney tumors and <1% of all soft tissue tumors
- Median age = 10.6 months
- Survival <25%
  - Worse prognosis with younger age
    - <10% for infants <6 months
    - <20% for infants <12 months
  - Worse prognosis with higher stage
    - Metastases frequently seen
Atypical Teratoid Rhabdoid Tumor

- Rare pediatric brain tumor
  - Approximately 1-2% of all pediatric brain tumors
- Historically misdiagnosed
  - Included within protocols for medulloblastoma and embryonal tumors
- Most often seen in infants
  - Median age <2 years
  - Occasionally in older children, rare in adults
- Anatomic location
  - ~60% in posterior fossa – predominantly in infants
  - Supratentorial – older child
  - Spinal – very rare
- 2-year survival <20% for children <3 years
- Molecular subgroups identified based on genomic profiling
Current Therapies for Rhabdoid Tumors

- Maximal surgical resection
- Radiation therapy (RT)
  - *Limitations*
    - RTK: dose and field of RT may affect other surrounding normal organs (e.g. GI, liver, lungs)
    - ATRT: craniospinal RT for infants and high-dose RT required are prohibitive
    - Radiation recall reported
- Intensive multi-agent chemotherapy
  - Alkylators, platinum, anthracyclines, methotrexate (ATRT only)
  - Intrathecal chemotherapy for ATRT
  - *Limitations*
    - RTK: single kidney post-nephrectomy limits nephrotoxic agents such as platinum
    - ATRT: neurotoxicity of methotrexate and intrathecal chemotherapy
- High dose chemotherapy/autologous stem cell transplant
  - Published and anecdotal evidence of activity in ATRT without need for RT
  - Not considered standard of care for extra-cranial MRT
Survival Outcomes in Rhabdoid Tumors

- ATRT: Von Hoff, et al., PBC 2011
2013 Accomplishments

Regulatory History

• Non-Hodgkin lymphoma (E7438-G000-101)
  – 2013: ANSM (France) approved first-in-human, monotherapy, phase 1/2 study of
tazemetostat in adult patients with advanced B cell lymphomas and solid tumors
  – 2015-16: IND/CTA/CTN acceptance in UK, Australia, Italy Canada, Germany and US
  for the phase 2 portion of this study

• Rhabdoid and non-rhabdoid INI1-negative or SMARCA4-negative tumors and
  synovial sarcoma
  – August 2015: IND accepted for INI1-negative solid tumors
  – December 2015: EZH-202 (phase 2 in adults) initiated in US
  – January 2016: EZH-102 (phase 1 in children) initiated in US
  – 2016: CTA/CTN acceptance of
    • EZH-102 – Canada, Australia, Denmark, UK, France and Germany
    • EZH-202 – Belgium, Italy, UK, France, Germany and Taiwan
  – February 2016: Orphan drug designation granted in US for the treatment of MRTs

• Mesothelioma (EZH-203)
  – May 2016: IND accepted for mesothelioma characterized by BAP1 loss-of-function
    • EU submissions in-progress
Clinical Trials Experience in Adults

• First-in-human
  - Phase 1 trial in France in patients with advanced solid tumors and B-cell non-Hodgkin lymphoma
    • Dose escalation, dose expansion, and clinical pharmacology cohorts

• Non-Hodgkin lymphoma
  - Global phase 2 trial for DLBCL and FL
    • Five cohorts – prospectively stratified according to cell-of-origin and EZH2 mutation status

• Rhabdoid tumors and other INI1-negative or SMARCA4-negative tumors
  - Global phase 2 trial
    • Five cohorts - 1) INI1- or SMARCA4-negative rhabdoid tumors, 2) relapsed/refractory synovial sarcoma, 3) other INI1 negative tumors, 4) renal medullary carcinoma and 5) epithelioid sarcoma
First-in-Human Phase 1 Trial
E7438-G000-101

- Population: adult patients with relapsed or refractory B-cell lymphoma or solid tumors
- Age: ≥18 years
- Study design: 3+3 dose-escalation
  - Dose levels: 100, 200, 400, 800 and 1600 mg BID
  - Expansion cohorts: 800 mg and 1600 mg BID
  - Food effect sub-study: 200 mg ± food, then 400 mg BID
  - Drug-drug interaction sub-study: 800 mg BID
- Primary endpoint: determination of RP2D/MTD
- Secondary endpoints: safety, PK, PD and tumor response (every 8 weeks)
# Patients – Solid Tumors

<table>
<thead>
<tr>
<th>Relapsed or refractory solid tumor</th>
<th>N=37</th>
</tr>
</thead>
<tbody>
<tr>
<td>INI 1-negative (SMARCB1)*</td>
<td></td>
</tr>
<tr>
<td>Malignant rhabdoid tumor</td>
<td>5</td>
</tr>
<tr>
<td>Epithelioid sarcoma</td>
<td>3</td>
</tr>
<tr>
<td>SMARCA4-negative*</td>
<td></td>
</tr>
<tr>
<td>Malignant rhabdoid tumor of ovary (SCCOHT)</td>
<td>2</td>
</tr>
<tr>
<td>Thoracic sarcoma</td>
<td>1</td>
</tr>
<tr>
<td>Synovial sarcoma</td>
<td>4</td>
</tr>
<tr>
<td>GI malignancy</td>
<td>10</td>
</tr>
<tr>
<td>GU malignancy</td>
<td>2</td>
</tr>
<tr>
<td>GYN malignancy (non-SCCOHT)</td>
<td>5</td>
</tr>
<tr>
<td>CNS tumor/other sarcoma</td>
<td>5</td>
</tr>
</tbody>
</table>

| Relapsed or refractory NHL         | N=21         |

* INI 1- or SMARCA4-negative by IHC

Data as of 07-Nov-2015
Source: Ribrag et al., ASH 2015
### Treatment-Emergent Adverse Events Observed in ≥5% of 89 Patients ¹

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>All Events n (%)</th>
<th>Treatment-Related Events n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any Grade</td>
<td>Grade 3/4</td>
</tr>
<tr>
<td>Patients with at least 1 TEAE</td>
<td>78 (88)</td>
<td>22 (25)</td>
</tr>
<tr>
<td>Asthenia</td>
<td>31 (35)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Nausea</td>
<td>14 (16)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>13 (15)</td>
<td>4 (5)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>12 (14)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Anemia</td>
<td>11 (12)</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Constipation</td>
<td>11 (12)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>7 (8)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>7 (8)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>6 (7)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Dry skin</td>
<td>6 (7)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>6 (7)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Muscle spasms</td>
<td>6 (7)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>5 (6)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>5 (6)</td>
<td>2 (2)</td>
</tr>
</tbody>
</table>

Data as of 15-Jan-2016  
Source: Investigators Brochure  

¹ Phase 1 and Phase 2 studies combined
Best Response in Patients with Solid Tumors

- Patients censored at time of progression
- INI1-negative
- SMARCA4-negative
- Other solid tumor

Data as of 31-Aug-2015
Source: Italiano et al., ECC 2015
CR in Patient with INI1-Negative Malignant Rhabdoid Tumor

Baseline

Week 4
June 23, 2014

Week 8: CR

Week 20

55 y.o. male
800 mg BID

INI1 IHC

Diagnosis + XRT

Surgery

Tazemetostat: ongoing response week 65+

Data as of 31-Aug-2015
Source: Italiano et al., ECC 2015

2013
2014
2015
Phase 1 Summary in Adults

- Safety profile as monotherapy is favorable for development as both single agent and combination therapy
- Tazemetostat demonstrates clinical activity as monotherapy in patients with both B-cell NHL and solid tumors
  - Relapsed or refractory DLBCL (both GCB and non-GCB), FL and MZL
    - Objective responses include both CR and PR
    - Responses are durable – patients ongoing at 24+ to 30+ months
  - **Relapsed INI1- and SMARCA4-negative tumors**
    - Malignant rhabdoid tumor, malignant rhabdoid tumor of ovary (SCCOHT), epithelioid sarcoma
    - Objective responses (CR and PR) observed
    - Additional patients with SD lasting ≥6 months observed
- Pharmacodynamic inhibition of H3K27me3 demonstrated in tumor tissue and in surrogate tissue (skin)
- Pharmacokinetic results demonstrate that tazemetostat may be taken without regard to meals and is a weak inducer of CYP3A4/5
- RP2D dose of 800 mg BID supported by safety, efficacy, PK/PD
EZH-102: Pediatric Phase 1 Study Overview and Design

- NCT02601937: “Phase 1 study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma”

- Phase 1, open-label, multi-center dose escalation and dose expansion study of tazemetostat administered twice daily (BID) using an oral suspension formulation in pediatric subjects

- Enrollment based upon local pathology with central confirmation (IHC)

- Eligible malignancies include:
  - Rhabdoid tumors: (ATRT, MRT, RTK, selected tumors with rhabdoid features)
  - INI1-negative tumors: (epithelioid sarcoma, epithelioid malignant peripheral nerve sheath tumors, extraskeletal myxoid chondrosarcoma, myoepithelial carcinoma, renal medullary carcinoma, undifferentiated chordoma, other tumors with Sponsor approval)
  - Synovial sarcoma with SS18-SSX rearrangement
“Rolling 6” dose escalation design
- Starting dose of 240 mg/m² BID derived from physiologically-based PK modeling of observed PK in adults
- Subjects evaluated for dose limiting toxicities in Cycle 1
- Dose levels:
  - 240 mg/m², 300 mg/m², 400 mg/m², and 520 mg/m² BID

Following dose escalation, dose expansion cohorts will enroll up to 60 subjects (n=20 in each cohort)
- Cohort 1: ATRT
- Cohort 2: extra-CNS rhabdoid tumors (MRT, RTK)
- Cohort 3: non-rhabdoid INI1-negative tumors
EZH-102: Study Endpoints

• Primary:
  – Dose Escalation: Identify dose-limiting toxicities and recommended phase 2 dose / maximum tolerated dose
  – Dose Expansion: Evaluate overall response rate (ORR)

• Secondary:
  – Dose Escalation: ORR and duration of response
  – Dose Expansion: Duration of response
  – Dose Escalation and Dose Expansion:
    • Progression-free survival and overall survival
    • Safety/tolerability
    • Pharmacokinetics

• Exploratory:
  – PK/PD, H3K27 methylation, tumor target gene expression and phenotypic markers, somatic mutation analysis of tumor tissue and blood derived from circulating DNA
EZH-102: Main Inclusion Criteria

- Age 6 months to 21 years
- Relapsed or refractory disease with no standard treatment options per local/regional standards of care and treating physician's discretion
- Local diagnostic pathology of original biopsy confirmed by CLIA/CAP certified laboratory documenting INI1 loss, SMARCA4 loss, or SS18-SSX rearrangement
- Measurable disease (dose expansion subjects only)
- For patients with CNS involvement, stable deficits at least 14 days prior to enrollment (seizures stable and controlled by anti-seizure medication at least 7 days)
EZH-102: Main Exclusion Criteria

- Received investigational drug within 30 days or five half-lives, whichever is longer, prior to the planned first dose of tazemetostat.
- For patients with CNS involvement (primary tumor or metastatic disease): Have any active bleeding, or new intratumoral hemorrhage of more than punctate size on Screening MRI obtained within 14 days of starting study drug, or known bleeding diathesis or treatment with anti-platelet or anti-thrombotic agents.
- Time from last prior anti-cancer therapy:
  - Investigational agent → 30 days or five half-lives
  - Cytotoxic chemotherapy → 21 days
  - Non-cytotoxic chemotherapy → 14 days
  - Immunotherapy (e.g. vaccine) → 6 weeks
  - Radiotherapy → 14 days (local); 21 days (stereotactic); 12 weeks (craniospinal, pelvic, total body irradiation)
  - Hematopoietic cell transplantation → 60 days
  - Hematopoietic growth factor → 14 days
## Enrollment (as of June 15, 2016)

<table>
<thead>
<tr>
<th>Dose Level</th>
<th>Age</th>
<th>Tumor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>240 mg/m²</td>
<td>2y 9m</td>
<td>MRT*</td>
</tr>
<tr>
<td></td>
<td>1y 11m</td>
<td>ATRT*</td>
</tr>
<tr>
<td></td>
<td>1y 7m</td>
<td>ATRT*</td>
</tr>
<tr>
<td></td>
<td>7y 4m</td>
<td>ATRT</td>
</tr>
<tr>
<td></td>
<td>2y 2m</td>
<td>ATRT</td>
</tr>
<tr>
<td></td>
<td>1y 9m</td>
<td>ATRT</td>
</tr>
<tr>
<td></td>
<td>2y 3m</td>
<td>ATRT</td>
</tr>
<tr>
<td></td>
<td>1y 1m</td>
<td>ATRT</td>
</tr>
<tr>
<td>300 mg/m²</td>
<td>14 y 10m</td>
<td>Anaplastic chordoma</td>
</tr>
<tr>
<td></td>
<td>1y 6m</td>
<td>Myoepithelial carcinoma</td>
</tr>
<tr>
<td></td>
<td>14 y</td>
<td>ATRT</td>
</tr>
<tr>
<td></td>
<td>15 y 6m</td>
<td>Epithelioid sarcoma</td>
</tr>
<tr>
<td></td>
<td>12 y</td>
<td>ATRT</td>
</tr>
<tr>
<td></td>
<td>13 y</td>
<td>MRT</td>
</tr>
<tr>
<td>400 mg/m²</td>
<td>1 y 6m</td>
<td>ATRT</td>
</tr>
<tr>
<td></td>
<td>6 y 11m</td>
<td>Malignant epithelioid neoplasm with rhabdoid features</td>
</tr>
</tbody>
</table>

* Not DLT evaluable
Pediatric Formulation

- EZH-102 currently uses extemporaneously prepared suspension of 30 mg/mL of tazemetostat in Ora-Sweet® (flavored syrup vehicle) with no other excipients
  - Two-week supply prepared at investigational pharmacy
  - Stable under refrigeration for 21 days
  - Compatible with nasogastric and gastric tubes

- Commercial formulation under development
  - Powder for re-constitution in unit-dose packets
  - Composed of thickener, sweetener, flavor and other processing/suspension aids (no preservative needed)
  - Re-constituted with ~10 ml of water
Development Program in Pediatrics

- Pediatric Preclinical Testing Program
  - Tazemetostat supplied to PPTP to test preclinical activity in large panel of pediatric tumors including rhabdoid tumors, Ewing sarcoma, osteosarcoma, and pediatric brain tumors
  - Results presented at 2015 AACR-NCI-EORTC Conference

- Pediatric MATCH
  - Pediatric counterpart to the NCI-MATCH trial in adults
  - Led by the Children’s Oncology Group
  - Will evaluate molecularly targeted therapies such as tazemetostat in children with advanced cancers who have few other treatment options
  - Tazemetostat proposed to be incorporated into Pediatric MATCH as one of the initial investigational agents to be tested
Challenges to Development

✓ Recruitment
  - Enrollment and US/EU/Australian site activations are on track and do not pose any major challenge to the pediatric clinical development

✓ Formulation
  - Proactively initiated development of a commercial formulation: powder for reconstitution in unit-dose packets to replace the extemporaneously prepared suspension prepared by the pharmacy and currently in use in clinical trials

❖ Rare disease
  - Evaluate clinical safety across multiple tumor types by enrolling up to 84 pediatric patients with genetically-defined INI1-negative and SMARCA4-negative tumors. Final sample size to be discussed with FDA
  - Safety profile of tazemetostat will be supplemented by the adult safety experience across all indications which currently include INI1-negative and SMARCA4-negative tumors, synovial sarcoma, B-cell NHL and mesothelioma

❖ High unmet medical need
  - Epizyme proposes to discuss with the Agency that this study be considered as adequate and well controlled in order to demonstrate efficacy and safety in this pediatric population

❖ Indication may be based on common genetics instead of histology
  - If supported by data, proposed labeled indication may include rhabdoid tumors with either loss of INI1 or of SMARCA4 and non-rhabdoid tumors with loss of INI1
• INI1-negative and SMARCA4-negative rhabdoid tumors are a Rare Disease with high unmet medical need
• Safety profile of tazemetostat as monotherapy is favorable for development as both single agent and combination therapy
• Tazemetostat demonstrates clinical activity as monotherapy in patients with both B-cell NHL and solid tumors
• Pediatric Study 102 may be considered for issuance of a Written Request
Tazemetostat for the Treatment of Pediatric Patients with Malignant Rhabdoid Tumors and Other INI 1-Negative Tumors

Presentation to the Pediatric Subcommittee of the Oncology Drugs Advisory Committee

June 28, 2016
Back-up Slides
Presented During Q&A
Thrombocytopenia and Neutropenia by Laboratory Results

<table>
<thead>
<tr>
<th>Subjects (n=82) with:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thrombocytopenia</strong></td>
<td>9 (11%)</td>
</tr>
<tr>
<td>Grade 3</td>
<td>8 (10%)</td>
</tr>
<tr>
<td>Grade 4</td>
<td>1 (1%)</td>
</tr>
<tr>
<td><strong>Neutropenia</strong></td>
<td>5 (6%)</td>
</tr>
<tr>
<td>Grade 3</td>
<td>2 (2%)</td>
</tr>
<tr>
<td>Grade 4</td>
<td>3 (4%)</td>
</tr>
</tbody>
</table>

* Determined by laboratory results, not by investigator assignment
Subjects are counted only once for their highest toxicity grade observed

Data as of 27-May-2016
Source: Morschhauser et al, ASH Lymphoma 2016
Synovial Sarcoma is a SWI/SNF Mutated Cancer

- Synovial Sarcoma
  - SS18-SSX [t(X;18)]
- Leukemia, T-ALL
- BCL7A, BCL7B, BCL7C
- BCL11A, BCL11B
- SS18
- PHF10, DPF1, DPF3
- DPF2

Other Cancers:
- HCC
- Colorectal Cancer, DLBCL
- Rhabdoid Tumors, Epithelioid Sarcoma
- Melanoma, GBM, Head and Neck, others
- Medulloblastoma, NSCLC, SCCOHT, others

Subunits:
- ARID1A
  - Ovarian Clear Cell Carcinoma, Gastric Cancer, Melanoma, others
- ARID1B
  - DLBCL, Head and Neck, Breast, others

Subunits:
- SMARCA1
- SMARCA2
- SMARCA4

Small Cell Lung Cancer, Gastric Cancer, Melanoma
- SMARCC1
- SMARCC2

Pancreatic Cancer, DLBCL, Head and Neck
- Clear Cell Meningioma

ALTERNATIVE TARGETING SUBUNITS
- ARID2
  - Melanoma, HCC, Myeloma
- PBRM1
  - RCC, DLBCL, Head and Neck
- BRD7
  - CLL

Adapted from Kadoch 2015
## RP2D Selection Summary

<table>
<thead>
<tr>
<th>Dose BI D</th>
<th>Efficacy</th>
<th>Safety</th>
<th>PK/ PD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Response in NHL (%)</td>
<td>Grade ≥3 TEAE *</td>
<td>H3K27 Inhibition Emax **</td>
</tr>
<tr>
<td>&lt;800 mg</td>
<td>2/9 (22%)</td>
<td>7/24 (29%)</td>
<td>-</td>
</tr>
<tr>
<td>800 mg</td>
<td>5/8 (62%)</td>
<td>3/19 (16%)</td>
<td>80%</td>
</tr>
<tr>
<td>1600 mg</td>
<td>2/4 (50%)</td>
<td>4/12 (33%)</td>
<td>84%</td>
</tr>
</tbody>
</table>

**H3K27 me3 in Skin**

### Baseline

- 200 mg
- 800 mg
- 1600 mg

### Week 4

- 200 mg
- 800 mg
- 1600 mg

### H3K27me3 vs. Exposure

* Treatment Emergent Adverse Events in all patients (n=55)
EZH2 Target Inhibition in Tumor Tissue

**Pre-Dose**

**Rhabdoid Tumor of Kidney**
INI 1-negative

H3K27me3
Diffuse positive 1+: 100% tumor

**Epithelioid Sarcoma**
INI 1-negative

H3K27me3
Diffuse positive 1+: 100% tumor

**Post-Dose: Week 4**

H3K27me3
Negative: 100% tumor

H3K27me3
Negative: 50% tumor
INI1/SMARCB1 Loss is the Predominant Molecular Feature of ATRT

Johann et al. Cancer Cell, 2016